150 related articles for article (PubMed ID: 38676765)
1. GLI1 polymorphisms influence remission rate and prognosis of young de novo acute myeloid leukemia patients treated with cytarabine-based chemotherapy.
Liu Y; Liu Y; Chen P; Chen G; Chen X
Ann Hematol; 2024 Jun; 103(6):1967-1977. PubMed ID: 38676765
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients.
Wang S; Yuan X; Liu Y; Zhu K; Chen P; Yan H; Zhang D; Li X; Zeng H; Zhao X; Chen X; Zhou G; Cao S
J Transl Med; 2019 Mar; 17(1):101. PubMed ID: 30922329
[TBL] [Abstract][Full Text] [Related]
3. Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).
Zhu KW; Chen P; Zhang DY; Yan H; Liu H; Cen LN; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Chen XP
J Transl Med; 2018 Apr; 16(1):90. PubMed ID: 29631596
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
Cao HX; Miao CF; Yan L; Tang P; Zhang LR; Sun L
J Transl Med; 2017 Nov; 15(1):235. PubMed ID: 29141648
[TBL] [Abstract][Full Text] [Related]
5. GLI1 reduces drug sensitivity by regulating cell cycle through PI3K/AKT/GSK3/CDK pathway in acute myeloid leukemia.
Zhou C; Du J; Zhao L; Liu W; Zhao T; Liang H; Fang P; Zhang K; Zeng H
Cell Death Dis; 2021 Mar; 12(3):231. PubMed ID: 33658491
[TBL] [Abstract][Full Text] [Related]
6. Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens.
Chen P; Zhu KW; Zhang DY; Yan H; Liu H; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Yang J; Chen XP
J Transl Med; 2018 Jul; 16(1):197. PubMed ID: 30016963
[TBL] [Abstract][Full Text] [Related]
7. E2F1 rs3213150 polymorphism influences cytarabine sensitivity and prognosis in patients with acute myeloid leukemia.
Liu Y; Chen P; Chen G; Chen X
Ann Hematol; 2023 Dec; 102(12):3345-3355. PubMed ID: 37665348
[TBL] [Abstract][Full Text] [Related]
8. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
Li R; Hu X; Wang L; Cheng H; Lv S; Zhang W; Wang J; Yang J; Song X
Am J Hematol; 2017 Jan; 92(1):12-17. PubMed ID: 27673579
[TBL] [Abstract][Full Text] [Related]
10. Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.
Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Martínez-Cuadrón D; Rojas L; Rodríguez-Veiga R; Boluda B; Sendra L; Cervera J; Poveda JL; Sanz MÁ; Aliño SF
Leuk Lymphoma; 2017 Dec; 58(12):2880-2894. PubMed ID: 28573946
[TBL] [Abstract][Full Text] [Related]
11. [Outcomes of adult patients with
Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2018 Jan; 39(1):15-21. PubMed ID: 29551027
[No Abstract] [Full Text] [Related]
12. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
[TBL] [Abstract][Full Text] [Related]
13. UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy.
Díaz-Santa J; Rodríguez-Romanos R; Osca G; Pratcorona M; Garrido A; Coll R; Moret C; Escoda L; Tormo M; Heras I; Arnan M; Vives S; Salamero O; Lloveras N; Bargay J; Sampol A; Cruz D; Garcia A; Quiñones T; Esteve J; Sierra J; Gallardo D;
Leukemia; 2020 Nov; 34(11):2925-2933. PubMed ID: 32152464
[TBL] [Abstract][Full Text] [Related]
14. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K
Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772
[TBL] [Abstract][Full Text] [Related]
15. High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial.
Heil G; Mitrou PS; Hoelzer D; Freund M; Link H; Ehninger G; Steinke B; Ohl S; Wandt H; Fackler-Schwalbe E
Ann Hematol; 1995 Nov; 71(5):219-25. PubMed ID: 7492624
[TBL] [Abstract][Full Text] [Related]
16. Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.
Amaki J; Onizuka M; Ohmachi K; Aoyama Y; Hara R; Ichiki A; Kawai H; Sato A; Miyamoto M; Toyosaki M; Machida S; Kojima M; Shirasugi Y; Kawada H; Ogawa Y; Ando K
Int J Hematol; 2015 Jun; 101(6):543-53. PubMed ID: 25735499
[TBL] [Abstract][Full Text] [Related]
17. Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.
Klco JM; Miller CA; Griffith M; Petti A; Spencer DH; Ketkar-Kulkarni S; Wartman LD; Christopher M; Lamprecht TL; Helton NM; Duncavage EJ; Payton JE; Baty J; Heath SE; Griffith OL; Shen D; Hundal J; Chang GS; Fulton R; O'Laughlin M; Fronick C; Magrini V; Demeter RT; Larson DE; Kulkarni S; Ozenberger BA; Welch JS; Walter MJ; Graubert TA; Westervelt P; Radich JP; Link DC; Mardis ER; DiPersio JF; Wilson RK; Ley TJ
JAMA; 2015 Aug; 314(8):811-22. PubMed ID: 26305651
[TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
Bao Y; Zhao J; Li ZZ
Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
[TBL] [Abstract][Full Text] [Related]
19. Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).
Zhu HH; Jiang H; Jiang Q; Jia JS; Qin YZ; Huang XJ
Leuk Res; 2016 May; 44():40-4. PubMed ID: 26994850
[TBL] [Abstract][Full Text] [Related]
20. Targeting GLI1 Suppresses Cell Growth and Enhances Chemosensitivity in CD34+ Enriched Acute Myeloid Leukemia Progenitor Cells.
Long B; Wang LX; Zheng FM; Lai SP; Xu DR; Hu Y; Lin DJ; Zhang XZ; Dong L; Long ZJ; Tong XZ; Liu Q
Cell Physiol Biochem; 2016; 38(4):1288-302. PubMed ID: 27008269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]